SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Innocoll Holdings plc To Contact The Firm Before Lead Plaintiff Deadline

NEW YORK, Jan. 25, 2017 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ:INNL) of the March 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all those who purchased Innocoll publicly traded securities between November 3, 2016 and December 29, 2016 (the “Class Period”).  The case, PEPICELLI v. INNOCOLL HOLDINGS PUBLIC LIMITED COMPANY et al, No. 2:17-cv-00341 was filed on January 24, 2017, and has been assigned to Judge Gene E.K. Pratter.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the Food and Drug Administration (“FDA”) in October 2016 for XARACOLL, a surgically implantable and bioresorbable bupivacaine-collagen matrix, was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Innocoll’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Specifically, on December 29, 2016, Innocoll disclosed via a press release that the Company received a Refusal to File letter from the FDA for XARACOLL. The press release stated, among other things, that the Company’s NDA submission “was not sufficiently complete to permit a substantive review.”

On this news, Innocoll’s share price fell from $1.77 on December 29, 2016 to a closing price of $0.69 on December 30, 2016—a $1.08 or a 61.02% drop.

Request more information now by clicking here: www.faruqilaw.com/INNL. There is no cost or obligation to you.

Take Action

If you invested in Innocoll common stock between November 3, 2016 and December 29, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/INNL. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding Innocoll’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330